|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Supplementary Table 2**. Kinases\* with luxeptinib IC50 or Kd values <25 nM | | | | |
| Cluster | Kinase | RBC IC50 (nM) | Carna IC50 (nM) | Discover X Kd (nM) |
| AURK | **AURK-A** | 0.38 | 25.5 | 2.9 |
|  | **AURK-B** | 3.7 | 32.7 | 3.1 |
|  | **AURK-C** | 3.0 | 14.8 | 1.1 |
| STE | **KHS (MAP4K5)** | 0.1 | - | 1.1 |
|  | **MST1 (STK4)** | 2.1 | 6.7 | 1.3 |
|  | **GLK (MAP4K3)** | 2.3 | - | 25 |
|  | **MST2 (STK3)** | 7.1 | - | 3.9 |
|  | **MST3 (STK24)** | 41.5 | - | 24 |
|  | **HPK1 (MAP4K1)** | 11.5 | - | 7.2 |
|  | **YSK4 (MAP3K19)** | 17.3 | - | 3.9 |
|  | **TNIK (TRAF2)h** | 4.1 | 99.5 | 4.7 |
|  | **MYO3A** | 8.2 | - | 13 |
|  | MYO3B | 4.2 | - | 76 |
|  | **SLK (STK2)** | 14.3 | - | 0.3 |
|  | MEK1 (MAP2K1) | 42.6 | 325.4 | 23 |
|  | **MEK3 (MAP2K3)** | - | - | 5.8 |
|  | **MEK4 (MAP2K4)** | - | - | 11 |
|  | **MEK5 (MAP2K5)** | - | - | 0.8 |
|  | **MEK6 (MAP2K6)** | - | - | 12 |
|  | **MST4** | - | - | 8.2 |
| OTHER | **PAK4 (SAK)** | 4.8 | - | 0.2 |
|  | LRRK2 | 13.4 | - | 260 |
|  | ERN2 | 14.8 | - | - |
|  | LOK (STK10) | 43.3 | - | 0.1 |
| \*Kinases for which the IC50 <25 nM in the Reaction Biology Corporation enzymatic assay (using [ATP] = Km for each kinase) or for which the KD < 25 nM in the Discover X competition binding assay. Kinases were considered as positive targets (bold font) if the IC50 and KD both were confirmed to be below 25 nM, or if the IC50 or KD was below 15 nM and data were available from only one assay system. The IC50 data from Carna (assay performed with [ATP] = 1 mM) are provided for comparative purposes. Kinases identified as positive targets (bold font) were introduced into the consensus composite scan of kinases in the human kinome shown in Fig. 1B | | | | |